The pathogenesis of type 1 diabetes (T1D) involves the interaction of the immune system with β cells. 12/15-lipoxygenase (12/15-LOX), an enzyme involved in arachidonic acid metabolism, is highly expressed in both β cells and macrophages. Global deletion of the gene encoding 12/15-LOX (Alox15) prevents diabetes in the NOD mouse (animal model for T1D) via reduction of proinflammatory cytokines produced by macrophages and islets. However, the role of 12/15-LOX in the macrophages during T1D development remains unclear. To address this issue, we generated myeloid lineage-specific Alox15 knockout mice (Alox15∆myel) on the NOD background and evaluated immune cell infiltration into the pancreas and in pancreatic lymph nodes, as well as diabetes outcome in these animals. Pancreas sections of Alox15∆Myel mice showed a decrease of lymphocyte infiltration compared to control littermates. Alox15∆Myel mice also showed a decreased frequency of IL-1β produced by macrophages (F480+IL1β+) and dendritic cells (CD11c+IL1β+) in the pLNs when compared to control mice. To clarify if Alox15 in myeloid cells mediates proinflammatory cytokines production by T cells, we performed a co-culture assay of Alox15-/- macrophages with naïve T cells. Alox15 deletion in macrophages impaired IFN-γ production from CD4+ T cells compared to WT macrophages. Furthermore, Alox15∆Myel mice showed a significant decrease in the incidence of spontaneous type 1 diabetes (<10%) compared to control mice (80%) (P<0.05). Alox15 deletion in macrophages led to increased β-cell mass and decreased insulitis in nondiabetic mice. Gene expression analysis in the islets showed increased expression of Pdx1 and Il-10 in islets of Alox15∆Myel mice. Together, these data suggest that myeloid-derived Alox15 promotes immune cell infiltration and inflammation in the pancreas leading to β-cell destruction and development of T1D.

Disclosure

A. Pineros: None. A. Kulkarni: None. K. Orr: None. L. Glenn: None. C.A. Reissaus: None. M. Hernandez-Perez: None. M.J. McDuffie: None. J. Nadler: None. M.A. Morris: Stock/Shareholder; Spouse/Partner; Becton, Dickinson and Company, Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Sanofi. R. Mirmira: Advisory Panel; Self; Hibercell, Sigilon Therapeutics, Veralox Therapeutics. Employee; Spouse/Partner; Eli Lilly and Company. S.A. Tersey: None.

Funding

National Institutes of Health (R01DK105588, P30DK097512 to R.M.)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.